McKesson Accelerate Provides Launchpad for Ideas, Collaboration and Progress

Over 1,500 stakeholders in community oncology gathered November 2–5, 2025 at the inaugural McKesson Accelerate conference to share ideas and solutions to navigate the challenges they confront in today’s dynamic healthcare landscape.   

Thought-provoking sessions led by renowned experts shed light on the trends and opportunities facing community oncology, such as rising costs, the complexity of novel therapies and precision medicine, reimbursement hurdles, artificial intelligence, leadership  and the evolving regulatory landscape.

Attendees acquired not only deeper knowledge on these critical issues, but actionable insights and solutions to innovate while elevating patient care and strengthening practice viability.

“Successfully managing the complexity of modern cancer care is extremely difficult in today’s environment,” said Jason Hammonds, President, Oncology & Multispecialty, McKesson. “For the past 20 years, McKesson has heavily invested in community oncology, and Accelerate provides practices the deep insights, tools and partnerships they need to succeed. Together, we are redefining cancer care to ensure community oncology is not just surviving, it’s thriving.”

Solutions to Manage Complexity, Enhance Care and Build Sustainability

More than just another industry event, Accelerate provided a launchpad for novel resources, idea sharing and connections to improve practice operations and cancer care in local communities.

The event featured a number of sessions highlighting the opportunity for collaboration with community oncology providers, biopharma leaders and key stakeholders, including in the Innovation Theater and Broadcast Center. These presentations showcased technologies, treatments and solutions that are transforming cancer care.

Biopharma exhibitors had the opportunity to highlight their latest advancements while facilitating insightful discussions with providers, clinicians and pharmacists around drug  development, data sharing and clinical trials.

“Oncology is at the heart of our strategy because we believe, together with our partners, we can advance community oncology, bring great healthcare closer to where patients live and truly impact their lives,” said Brian Tyler, CEO, McKesson. “It’s a privilege to stand alongside providers and witness the incredible advancements they make every day. We are committed to supporting community oncologists to make their lives easier, amplify their impact on patient care and help win the fight against cancer.”

Accelerate 2025: Good Outcomes Happen When Great Minds Come Together

Bringing together 1,500 oncology leaders at Accelerate enabled a tremendous opportunity for problem-solving, networking and  productive conversations.

The attendees, each with their own  unique perspectives and skills, learned from one another, generated fresh ideas and formed connections that will be mutually beneficial.

McKesson Accelerate is poised to become the essential annual event  for community oncology, setting the stage for trailblazers and visionaries  to come together and shape the future of cancer care.

Next year’s gathering is positioned to deliver a valuable opportunity for biopharma  leaders to connect with top oncology physicians, clinicians, influential  decision-makers and industry innovators — all in one place.

Accelerate is where meaningful collaborations ignite, breakthrough ideas emerge and  transformative solutions take root. By curating a presence at Accelerate, biopharma leaders will be at the forefront of driving progress, expanding  their impact and forging lasting partnerships that elevate community  cancer care for years to come.